PMID- 30787627
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 12
DP  - 2019
TI  - Canagliflozin review - safety and efficacy profile in patients with T2DM.
PG  - 209-215
LID - 10.2147/DMSO.S184437 [doi]
AB  - Canagliflozin is a sodium glucose-cotransporter (SGLT) receptor inhibitor 
      approved for the treatment of type 2 diabetes mellitus (T2DM). This article 
      reviews the mechanism of action of SGLT-2 receptor inhibitors and the efficacy of 
      canagliflozin as an antidiabetic agent, its cardiovascular and renal benefits, 
      and safety profile. During the development of canagliflozin, Phase II trials 
      showed an improvement in cardiac and renal biomarkers such as blood pressure, 
      body weight, and albuminuria. The large CANVAS program showed that canagliflozin 
      reduced the composite cardiovascular outcome of cardiovascular death, nonfatal 
      myocardial infarction, or nonfatal stroke. The CANVAS program also showed a 
      possible benefit of canagliflozin on a renal composite of sustained 40% reduction 
      in estimated glomerular filtration rate, the need for renal replacement therapy, 
      or death from renal causes. The safety profile of canagliflozin has been well 
      characterized, and known side effects such as mycotic genital infections were 
      confirmed in CANVAS. However, an increased risk of amputations was observed in 
      CANVAS that requires further study. Overall, canagliflozin is an effective 
      antidiabetic medication with cardiovascular and likely renal benefits, and with a 
      generally well-tolerated safety profile. Results from the CREDENCE trial will 
      further evaluate the safety and potential renal benefits of canagliflozin in 
      patients with established diabetic nephropathy.
FAU - Jakher, Haroon
AU  - Jakher H
AD  - Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, 
      USA, hjakher@stanford.edu.
FAU - Chang, Tara I
AU  - Chang TI
AD  - Division of Nephrology, Department of Medicine, Stanford University School of 
      Medicine, Palo Alto, CA, USA.
FAU - Tan, Marilyn
AU  - Tan M
AD  - Division of Endocrinology, Department of Medicine, Stanford University School of 
      Medicine, Palo Alto, CA, USA.
FAU - Mahaffey, Kenneth W
AU  - Mahaffey KW
AD  - Stanford Center for Clinical Research, Department of Medicine, Stanford 
      University School of Medicine, Palo Alto, CA, USA.
LA  - eng
GR  - K24 DK085446/DK/NIDDK NIH HHS/United States
GR  - T32 DK007357/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20190201
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC6363491
OTO - NOTNLM
OT  - CANVAS
OT  - Invokana(R)
OT  - canagliflozin
OT  - cardiac
OT  - diabetes
OT  - renal
OT  - sodium glucose-cotransporter
COIS- Disclosure HJ reports no financial disclosures. KWM's financial disclosures can 
      be viewed at http://med.stanford.edu/profiles/kenneth-mahaffey. TIC serves as the 
      Co-US National Leader of CREDENCE and reports receiving consulting fees from 
      Janssen Research and Development, LLC, and Novo Nordisk. MT reports no financial 
      disclosures. The authors report no other conflicts of interest in this work.
EDAT- 2019/02/23 06:00
MHDA- 2019/02/23 06:01
PMCR- 2019/02/01
CRDT- 2019/02/22 06:00
PHST- 2019/02/22 06:00 [entrez]
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/02/23 06:01 [medline]
PHST- 2019/02/01 00:00 [pmc-release]
AID - dmso-12-209 [pii]
AID - 10.2147/DMSO.S184437 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2019 Feb 1;12:209-215. doi: 10.2147/DMSO.S184437. 
      eCollection 2019.